# Lodo Therapeutics Corporation

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/lodo-therapeutics

- Industry: Pharmaceuticals
- Headquarters: New York, US
- Website: www.lodotherapeutics.com
- Total disclosed funding: $17M
- Latest round: Series A (Jan 11, 2016)
- Investors on record: 13

## About

Lodo Therapeutics Corporation is a biotechnology firm specializing in the discovery and development of new therapeutics by harnessing the power of microbial biodiversity and advanced synthetic biology techniques.Lodo Therapeutics Corporation focuses on the discovery of novel therapeutics derived from microbial sources. Founded in 2015, the company is headquartered in New York, US, and has engaged in two significant deals as of May 2021. The latest funding round was a SERIES A, where Lodo raised USD 17.00 mn from investors, including 180 Degree Capital and the Bill & Melinda Gates Foundation. The company was acquired by Zymerge, Inc. in May 2021.Lodo Therapeutics offers a range of research and development tools and solutions aimed at drug discovery, leveraging microbial genetics and synthetic biology. Their services cater to various applications including pharmaceutical development and biomanufacturing, focusing on creating innovative therapeutic compounds.Lodo Therapeutics generates revenue through customized R&D projects and strategic partnerships that allow clients to utilize their microbial discovery capabilities. The company engages in transactions on a B2B basis, with varying pricing structures based on project complexity and scope.Looking ahead, Lodo Therapeutics plans to expand its portfolio with new therapeutic products derived from its microbial research initiatives. The recent funding from May 2021 will support these projects and enable the company to explore new markets, particularly in North America and Europe, by enhancing its collaborative efforts with pharmaceutical partners. Specific timelines for product releases and market expansions are currently under strategic development.

## Funding rounds

- Series A, Jan 11, 2016, $17M — ARCH Venture Partners, Alexandria Venture Investments, 180 Degree Capital, Johnson & Johnson, Inc., Pfizer Venture Investments, Bill & Melinda Gates Foundation, AbbVie Ventures, Accelerator Life Science Partners, Eli Lilly & Company, Partnership Fund for New York City, Watson Group Investments, Innovate NY Fund, Wuxi AppTec Group

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series A
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series A
- 180 Degree Capital (https://capitalatlas.ai/funds/180-degree-capital) — Series A
- Johnson & Johnson, Inc. — Series A
- Pfizer Venture Investments (https://capitalatlas.ai/funds/pfizer-venture-investments) — Series A
- Bill & Melinda Gates Foundation — Series A
- AbbVie Ventures (https://capitalatlas.ai/funds/abbvie-ventures) — Series A
- Accelerator Life Science Partners (https://capitalatlas.ai/funds/accelerator-life-science-partners) — Series A
- Eli Lilly & Company — Series A
- Partnership Fund for New York City (https://capitalatlas.ai/funds/partnership-fund-for-new-york-city) — Series A
- Watson Group Investments (https://capitalatlas.ai/funds/watson-group-investments) — Series A
- Innovate NY Fund — Series A
- Wuxi AppTec Group — Series A